BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

# Accelerating AIâ??s Role in Biopharma Innovation

01 May 2026 | Views | By Atul Kurani, Vice President, Global Head for Medical Practice & IoT, Capgemini Engineering

**Biopharma research & development (R&D) is entering a new era of transformation, driven by growing unmet medical needs and constrained innovation pathways. The demand for new medicines has never been greater, with complex and previously untreatable diseases reshaping the global health scenario. The pressure on the industry to respond is urgent. Yet rising costs of investment and drug development timelines increasingly determine which life-saving therapies reach patients and which donâ??t. Against this backdrop, recent breakthroughs in artificial intelligence (AI) and generative AI (GenAI) offer a critical opportunity. These technologies enable biopharma organisations to uncover hidden inefficiencies, streamline key stages of discovery and development, and ultimately reshape the economics of R&D, advancing the delivery of new treatments to patients who need them the most.**

AI is expected to address these structural challenges across the R&D value chain. It can reduce early-stage failures, predict biological relevance, and shorten discovery timelines, with quantifiable, industry-validated impact. The technology can cut preclinical R&D costs significantly, driven by improvements in target selection, virtual screening, and molecule property prediction. Discovery cycles are likely to become more efficient, shrinking from years to months. Across the drug lifecycle, lower costs and shorter development cycles are expected, varying by molecule complexity and degree of enterprise AI adoption. AI can also accelerate regulatory submissions by automating data compilation across internal and external sources. It can enhance quality by anticipating regulator queries and embedding responses upfront.

***Transforming Drug Discovery***

AI is shifting drug discovery from traditional trial-and-error to computation-led, in silico pipelines. Modern approaches integrate computer-aided drug design (CADD), molecular docking, physics-based simulations, and deep-learning–driven generative models to evaluate vast chemical spaces rapidly. Machine learning (ML) enables ultra-large virtual screening of millions of molecules in days, predicts drug target interactions with high precision, and optimises molecular properties. This computational acceleration has powered breakthroughs such as AI-generated Parkinson's candidates exploring novel disease modifying pathways.

***Personalising Precision Medicine***

AI has become the analytical backbone of precision medicine, integrating genomic sequences, clinical histories, radiology, pathology, and patient-level phenotypes into unified predictive frameworks. This multimodal fusion enables highly individualised treatment pathways. In oncology, advanced AI agents using multimodal tools are achieving pinpoint accuracy in tool usage and clinical decision-making, outperforming standard models. AI models such as DeepMind's AlphaFold are transformative for precision medicine and oncology. It provides accurate protein structure predictions, allowing researchers to understand disease-driving mutations, design personalised therapeutics, and model protein-to-protein interactions at patient-specific mutation sites.

***Optimising Clinical Trials***

Organisations are leveraging AI to enhance patient recruitment, improve site selection, forecast trial outcomes, design dosage schedules for patients, and predict adverse effects—transforming how clinical trials run. AI-powered monitoring makes trials faster, safer, and more efficient. The implications are important: clinical development accounts for a major portion of the total drug development costs, making it by far the most expensive stage. Gains in clinical trials will guide the economics of bringing new drugs to market.

### *Augmenting Regulatory Workflows*

Regulators are increasingly accepting AI-generated evidence and advanced data-analytics outputs, marking a major shift in regulatory science. AI now automates protocol reviews, flagging inconsistencies, missing elements, eligibility misalignments, and statistical design flaws before human review. This reduces early development timelines by several weeks and prevents costly amendments. Equally significant is AI-driven document generation, where models trained on regulatory schemas can automatically compile clinical study reports and investigator brochures, enabling generation of submission-ready dossiers.

### *Enabling Smart Manufacturing*

AI ensures predictive quality control, reduces batch failures, and optimises pharmaceutical production. Smart manufacturing systems powered by AI and Internet of Things (IoT) allow continuous monitoring of critical process parameters, flagging deviations in real time before they escalate and predicting equipment failures before they occur. Digital twins help teams simulate and optimise process conditions without interrupting live production.

In supply chains, AI forecasts demand, prevents stockouts, and improves medicine distribution across global networks. AI-enabled track-and-trace systems go beyond traditional serialisation, using ML to monitor end-to-end product movement across manufacturing sites, distribution hubs, cold-chain routes, and international borders. They deliver real-time visibility of product location, temperature, and chain of custody, while instantly detecting diversions, counterfeits, or cold-chain breaches.

### *Driving Enterprise-Scale Transformation*

Biopharma is rapidly shifting from scattered, one-off AI pilots to integrated, enterprise-wide operating models that embed computation intelligence into every stage of the drug lifecycle. Organisations are building unified data fabrics, model hubs, and reusable AI services connecting discovery, development, manufacturing, regulatory, and commercial teams. AI is becoming the backbone of end-to-end R&D, powering in silico target discovery, generative molecule design, AI-orchestrated clinical trials, real-time manufacturing optimisation, and predictive commercial analytics.

A case in point is the landmark Eli Lilly–Insilico Medicine deal. Valued around $2.7-$2.8 billion, the deal signals pharma's growing trust in AI-generated drug candidates. Insilico's AI platform identifies targets, designs and molecules and predicts biological behaviour, accelerating early-stage R&D. Eli Lilly's investment validates AI as a credible enabler and engine for drug discovery.

### *Scaling Global Biopharma Innovation: India's Role*

India's role in global biopharma innovation is being reshaped as multinational pharma companies increasingly establish Global Capability Centers (GCCs) in the country to drive AI-led drug discovery, digital clinical development, and advanced analytics. India's life sciences & healthcare GCC sector is expected to grow significantly in the coming years, with global drug makers relying on these hubs for AI-powered discovery, clinical trial analytics, regulatory operations, and commercial insights.

This reflects a broader change: India is moving beyond its identity as a high-volume, low-cost generic manufacturer to a strategic contributor to computational R&D and biologics innovation. India's pharma industry is now integrating GenAI, AI/ML, and large-scale data platforms to shorten drug development timelines. It is no longer the 'pharmacy of the world'; it is strengthening its position as a co-innovation engine, shaping next-generation therapeutics, biologics, and AI-driven R&D for global markets.

### *Building Guardrails for Meaningful Impact*

As AI continues to reshape biopharma innovation, its true impact will depend on technological capability as well as on the guardrails that govern its use. While operational readiness to scale AI in R&D is key, getting the organisational culture right is crucial because AI requires people to make it work properly, a point sometimes lost amid talk of technological advances. It is also imperative to build AI and data platforms to establish the R&D foundation and own the infrastructure and knowledge needed to gain long-term strategic advantage from AI. Ensuring data integrity, regulatory alignment, model transparency, and ethical deployment will be essential to realising AI's full potential across the drug discovery and development lifecycle while maintaining trust of patients and regulators.

Atul Kurani, Vice President, Global Head for Medical Practice & IoT, Capgemini Engineering